Straits Times Index
3,310.28 +10.28 (+0.31%) Nikkei
38,585.70 -47.32 (-0.12%) Hang Seng
18,073.35 -261.97 (-1.43%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,595.67 -871.75 (-1.33%) CMC Crypto 200
1,353.71 -6.62 (-0.49%)
CRL Aug 2024 220.000 put
- Zacks
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
- Business Wire
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
WILMINGTON, Mass., June 17, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisory s
- Zacks
Charles River (CRL) Partners to Reduce Animal Research Usage
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
